azithromycin + ampicillin + amoxicillin

This therapeutic regimen, evaluated by Sheba Medical Center, combines the macrolide antibiotic azithromycin with a standard course of ampicillin and amoxicillin for the management of late preterm premature rupture of membranes (PPROM) occurring between 34.0 and 36.6 weeks of pregnancy. Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms, thereby interfering with microbial protein synthesis. Ampicillin and amoxicillin are beta-lactam antibiotics that inhibit the synthesis of the bacterial cell wall by binding to penicillin-binding proteins (PBPs). The regimen specifically involves intravenous ampicillin followed by oral amoxicillin, with the addition of a single oral dose of azithromycin. The primary objective of this combination therapy in the context of PPROM is to improve neonatal outcomes by reducing the incidence of infectious complications, such as neonatal sepsis and chorioamnionitis, and potentially extending the latency period before delivery.

Brand names

ZithromaxAmoxilPrincipen

Other names

Azithromycin and Ampicillin for Late PPROMazithromycin-Sheba Medical Center-preterm premature rupture of membranes